Novo Nordisk weight loss drugs linked to rare eye condition: study

A box of Ozempic and its contents on a table in Dudley, North Tyneside, UK, October 31, 2023.

George Frey | Reuters

Investors at Novo Nordisk appeared unfazed Thursday by a critical Harvard report linking weight-loss drugs to a rare eye condition.

Semaglutide, found in weight-loss drugs such as Ozempic and Novo Nordisk’s Wegovy, may be linked to an increased risk of a rare eye disease, a Harvard Medical School study has found.

Leave a Comment